Clinical trials: Genital Neoplasm
Prostate Cancer
Calcitriol Plus Dexamethasone in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Combining calcitriol with dexamethasone may increase the effectiveness of therapy by making cancer cells more sensitive to dexamethasone.
- Trial name
- NCT00010231
- Testing
- calcitriol, dexamethasone
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Pittsburgh
HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
The goal of this study is to determine the feasibility of administration of a single dose of E7 TCR-T cells as induction therapy prior to definitive treatment (chemoradiation or surgery) of locoregionally advanced HPV-associated…
- Conditions
- HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT05639972
- Testing
- E7 TCR-T cells, Aldesleukin
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Christian Hinrichs
Prostatic Neoplasms
Hypofractionated Intensity Modulated and Image Guided Radiotherapy for Localized Prostate Cancer
Hypofractionated intensity modulated and image guided radiotherapy (HypoIGRT) with fewer high-fraction-size treatments would be beneficial for prostate cancer because it would deliver a larger biological-equivalent dose to the…
- Trial name
- NCT02651896
- Testing
- HypoIGRT
- Where
- 2 sites in Brazil
- Volunteers
- 130 people
- Sponsor
- Hospital Sirio-Libanes
Cervical Cancer, Cervix Cancer
Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer
Cervical cancer is the second-most common cancer in the world and is a leading cause of cancer death among women in developing countries.
- Conditions
- Cervical Cancer, Cervix Cancer, Cervix Neoplasm
- Trial name
- NCT04651127
- Testing
- Toripalimab + Chidamide
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Sun Yat-sen University
Endometrial Cancer
Lymphoseek as Lymphoid Tissue Targeting Agent in Patients With Cancer of the Endometrium
Part of standard treatment for endometrial cancer is to remove one or more groups of lymph nodes (lymph node dissection). Lymph nodes are small, bean-shaped organs located within the body throughout the lymphatic system (the…
- Trial name
- NCT02589366
- Testing
- Lymphoseek plus Vital Blue Dye
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of California, San Diego
Tumor, Ovarian Cancer
Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer
This is a multicenter, open-label, two-arm, 2-stage, Phase 2 study of NKTR-102 in patients with metastatic or locally advanced platinum-resistant ovarian cancer.
- Trial name
- NCT00806156
- Testing
- NKTR-102 q14d, NKTR-102 q21d
- Where
- 20 sites in United States, Belgium and 1 more
- Volunteers
- 178 people
- Sponsor
- Nektar Therapeutics
PCOS (Polycystic Ovary Syndrome)
The Physical and Mental Impact of ART: IVM vs Conventional Ovarian Stimulation
Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine conditions, affecting around 10% of women in reproductive age (ESHRE PCOS guideline, 2023).
- Trial name
- QolART (NCT07274202)
- Testing
- Questionnaires
- Volunteers
- 84 people
- Sponsor
- Universitair Ziekenhuis Brussel
Uterine Cancer
Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation
This is an open-label treatment program following basic prescribing information for patients with recurrent UPSC (Uterine Papillary Serous Carcinoma) to provide access to everolimus and limited treatment alternatives.
- Trial name
- NCT03285802
- Testing
- Letrozole, Everolimus
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Greater Baltimore Medical Center
BRCA1 Gene Mutation, BRCA2 Gene Mutation
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
This phase II trial studies how well pembrolizumab works in treating participants with cancer that has spread to other places in the body, has come back or has spread to nearby tissues or lymph nodes.
- Conditions
- BRCA1 Gene Mutation, BRCA2 Gene Mutation, Locally Advanced Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT03428802
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Rutgers, The State University of New Jersey
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
This randomized phase III trial studies bevacizumab and intravenous (given into a vein) chemotherapy to see how well they work compared with bevacizumab and intraperitoneal (given into the abdominal cavity) chemotherapy in…
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma
- Trial name
- NCT00951496
- Testing
- Bevacizumab, Carboplatin, Cisplatin
- Where
- 503 sites in United States
- Volunteers
- 1,560 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Cancer, Endometrial Neoplasm
Precision Medicine Applied to the Study of Endometrial Cancer: Application of NGS for Molecular Classification
In recent years, knowledge about cancer biology has expanded significantly. The study of gene expression profiles has revealed the heterogeneous nature and potential reclassification of the various tumor subtypes based on…
- Trial name
- NCT07006103
- Volunteers
- 400 people
- Sponsor
- Hospital Italiano de Buenos Aires
Prostate Cancer
TAK-700 in Castration Resistant Prostate Cancer
The objective of this randomized phase II open label trial is to determine the anti-tumor activity of TAK-700 (Orteronel) as compared to bicalutamide in terms of clinical progression-free survival in prostate cancer patients who…
- Trial name
- NCT01658527
- Testing
- Orteronel, Bicalutamide
- Where
- 4 sites in Belgium
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Ovarian Cancer
Evaluation of Prognostic Factors for Tubo-ovarian Cancer in France
Evaluation of the following prognostic factors in France, based on national quotation data: volume per center, patient age, geographic distance from a clinical center, delay for chemotherapy,Upfront surgery.
- Trial name
- Pro-TOCa (NCT05204342)
- Where
- France
- Volunteers
- 22,500 people
- Sponsor
- University Hospital, Montpellier
Cervical Cancer
DX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the Cervix
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating women who have advanced or…
- Trial name
- NCT00004866
- Testing
- exatecan mesylate
- Where
- 6 sites in United States
- Sponsor
- Daiichi Sankyo
Genital Warts
Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts
Large genital warts are frequently diagnosed in general gynaecology and oncology clinics in South Africa. Medical and destructive therapy for small warts is generally very effective, however unique problems posed by large or…
- Trial name
- TheraVACCS (NCT02750202)
- Testing
- Quadrivalent HPV vaccine, Hepatitis B vaccine
- Where
- 2 sites in South Africa
- Volunteers
- 52 people
- Sponsor
- University of Pretoria
Prostate Cancer
Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue
Background: Prostate cancer is the most common noncutaneous cancer among men in the U.S. Researchers want to study blood, tissue, and fluid samples of people with prostate cancer.
- Trial name
- NCT02594202
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer
Characterization of Ovarian Cancer Stem Cell
Specific aims: Identification and characterization of cancer stem cell-like population (cancer stem cells or cancer initiating cells) from primary tumor tissue, primary ascites and peripheral blood of ovarian cancer patients and…
- Trial name
- NCT01367353
- Testing
- surgery or debulking surgery
- Where
- Taiwan
- Volunteers
- 250 people
- Sponsor
- National Taiwan University Hospital
Endometrial Cancer, Endometrial Neoplasms
Robotic-assisted Versus Conventional Laparoscopic Surgery in Obese Patients With Early Endometrial Cancer
Data across literature suggest that robotic surgery may offer benefit specifically in patient with morbid obesity with endometrial cancer, but to date no randomized trials have been conducted to confirm these observations.
- Conditions
- Endometrial Cancer, Endometrial Neoplasms, Obesity, Morbid, Gynecologic Cancer
- Trial name
- RObese (NCT05974995)
- Testing
- Robot-assisted surgery, Laparoscopic surgery
- Where
- Italy
- Volunteers
- 566 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Solid Tumors
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-4630 monotherapy in adult participants with relapsed/refractory solid tumors…
- Trial name
- NCT03634982
- Testing
- RMC-4630
- Where
- 12 sites in United States
- Volunteers
- 133 people
- Sponsor
- Revolution Medicines, Inc.
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- EXCEED (NCT06238479)
- Testing
- LY4101174
- Where
- 28 sites in United States, Australia and 5 more
- Volunteers
- 490 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.